Perrigo(US:PRGO) ZACKS·2025-02-28 01:31Core Insights - Perrigo reported revenue of $1.14 billion for the quarter ended December 2024, a decrease of 1.6% year-over-year, and an EPS of $0.93, up from $0.86 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $1.2 billion, resulting in a surprise of -4.77%, while the EPS exceeded the consensus estimate of $0.92 by +1.09% [1] Financial Performance - Net Sales for Consumer Self-Care Americas (CSCA) were $744.10 million, below the average estimate of $766.89 million, with no year-over-year change [4] - Net Sales for Consumer Self-Care International (CSCI) reached $394.10 million, compared to the average estimate of $422.82 million, reflecting a year-over-year decline of 4.5% [4] - Specific categories within CSCA showed varied performance: - Oral care sales were $70.60 million, down 7.4% year-over-year and below the estimate of $72.34 million [4] - Nutrition sales increased by 14% to $145.70 million, slightly below the estimate of $147.32 million [4] - Healthy Lifestyle sales were $85.50 million, down 6.7% year-over-year, and below the estimate of $92.30 million [4] - Upper Respiratory sales were $130.30 million, down 4.9% year-over-year, and below the estimate of $133.24 million [4] Profitability Metrics - Adjusted Gross Profit for Consumer Self-Care International (CSCI) was $194.40 million, below the average estimate of $220.42 million [4] - Adjusted Gross Profit for Consumer Self-Care Americas (CSCA) was $229.10 million, also below the average estimate of $256.58 million [4] Stock Performance - Perrigo's shares returned +0.9% over the past month, contrasting with a -2.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]